Therapeutic potential of orlistat - bupropion treatment on high fat diet-induced lipotoxicity

• Published in: Toxicology and environmental health sciences Vol. 7; no. 5; pp. 262 - 271
• Main Authors: Hassanein, Nahed M. A., Elwy, Abdel-Hamid M., Tabl, Ghada A., Al-Mallah, Takhreed H.Y.
• Format: Journal Article
• Language: English
• Published: Seoul Korean Society of Environmental Risk Assessment and Health Science 01.12.2015
• Subjects: Biomedical and Life Sciences; Biomedicine; Environmental Health; Pharmacology/Toxicology; Rapid Communication; Obesity; Bupropion; Adipose tissue; Leptin; HFD; Dyslipidemia; Orlistat
• ISSN: 2005-9752; 2233-7784
• DOI: 10.1007/s13530-015-0247-8

This study was designed to investigate the possibility of achieving a combined benefit of the therapeutic dose of orlistat and half that of bupropion treatment on some obesity related parameters in high fat diet (HFD)-induced obesity model. Female C57BL/6 mice were fed HFD ad libitum for 8 weeks, then treated with either orlistat (10 mg/kg, p.o. daily), bupropion (30 mg/kg, p.o daily) or their combined treatment for 4 weeks. The results revealed that HFD induced increases in obesity related parameters (body and fat weights, adipocyte size, lipid profile, leptin level, liver nitrate/nitrite content, hepatic fatty changes and bone marrow adipoblasts). The changes in lipid profile included cholesterol, low density lipoprotein (LDL) and high density lipoprotein (HDL) levels. Although drugs regimen duration was short, the findings demonstrated ameliorative effect of the combined treatment on all studied parameters with more pronounced effect on adipocyte size, liver and bone marrow histology.